FDA Approves ZEPBOUND — Eli Lilly and Company

Eli Lilly’s ZEPBOUND (tirzepatide) has received FDA approval to treat adults with diabetes mellitus type 2, significantly expanding the company’s dominance in the rapidly growing obesity and metabolic disease market and amplifying competitive pressure on rival pharma firms. The approval of this compounded once-weekly injectable at a potentially more accessible price point aims to broaden patient access to GLP-1 therapies, driving projected wins in net new users.